Generex Biotechnology Corp. (fka GNBTQ)

[lexi2004]

This is from the Street.com's report on GNBT that I found in the research section of TDAmeritrade.

FINANCIAL ANALYSIS
GENEREX BIOTECHNOLOGY CORP's gross profit margin for the first quarter of its fiscal year 2010 has
significantly decreased when compared to the same period a year ago. Even though sales decreased, the net
income has increased. GENEREX BIOTECHNOLOGY CORP is extremely liquid. Currently, the Quick Ratio is 2.93
which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased
from the same period last year, indicating improving cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 71.77% from the same quarter
last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial
difficulties in the near future.